Alopecia areata
Therapeutic area
Dermatology
Rare disease
No
- Definition
- Loss of scalp and body hair involving microscopically inflammatory patchy areas.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Alopecia areata
- Therapeutic area
- Dermatology
- alopecia areata
- alopecia areata
- alopecia circumscripta
- All therapeutic areas
- Dermatology
- Severity
- Mild
- MONDO ID
- MONDO:0005340
- Parent condition
- MONDO:0004907
Related records
Broader conditions (8)
- Alopecia
- Disease
- Disease by body system or component
- Disorder of pilosebaceous unit
- Hair anomaly
- Human disease
- Integumentary system disorder
- Skin appendage disorder
Narrower conditions (2)
- Alopecia areata 1
- Diffuse alopecia areata
Trials (217)
- 1565nm Non-ablative Fractional Laser Treat Alopecia Areata
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata
- A Clinical Trial to Evaluate the Efficacy of Abatacept in Moderate to Severe Alopecia Areata
- A First in Human Single and Multiple Ascending Dose and Open Label Food Effect Study of OR-101 in Healthy Subjects
- A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
- A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
- A Novel Formulation of Sildenafil-loaded Nanocarriers for Treatment of Alopecia Areata
- A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)
- A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)
- A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
- A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)
- A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata
- A Phase II Study in Patients With Alopecia Areata
- A Pilot Cohort Study of Risk Factors and Novel Methods of Skin Lesion Assessments in Adults With Atopic Dermatitis, Alopecia Areata, Psoriasis or Vitiligo
- A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata
- A Prospective, Observational Study of Clinician and Patient-reported Outcomes in Patients With Dermatological Conditions
- A Randomised Control Trial of Integrative Cognitive Behavioural Therapy for Alopecia
- A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
- A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
- A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
Approved drugs (2)
- Deuruxolitinib phosphate
- Ritlecitinib tosylate
Drugs in development (45)
- Abatacept Phase 2
- Aldesleukin Phase 1
- Amlitelimab Phase 2
- Aslan-003 Phase 2
- Baricitinib Phase 3
- Bempikibart Phase 2
- Betamethasone valerate Phase 1
- Bexarotene Phase 2
- Bimatoprost Phase 1
- Brepocitinib Phase 2
- Clobetasol propionate Phase 3
- Crisaborole Phase 2
- Daxdilimab Phase 2
- Delgocitinib Phase 2
- Deucravacitinib Phase 2
- Deuruxolitinib Phase 3
- Diphencyprone Phase 3
- Diphtheria toxoid Phase 3
- Dupilumab Phase 2
- Ergocalciferol Phase 1
Other linked drugs (6)
- Alefacept
- Apremilast
- Botulinum toxin type A
- Calcipotriene
- Onabotulinumtoxina
- Trichloroacetic acid